Citrate or heparin to keep blood from clotting during hemodiafiltration
Compares citrate and heparin as blood thinners in adults on long-term dialysis.
Plain-language title generated from the registry record
Registry title: Comparison of Citrate and Heparin Anticoagulation During Postdilution Hemodiafiltration
Key facts
- Where
- Ljubljana, SloveniaSee the site
Where in Slovenia
- University Medical Centre LjubljanaLjubljana, SloveniaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Medical Centre Ljubljana
- Trial code
- NCT07618858
- Record updated
- 1 June 2026
- Original description
This randomized crossover clinical trial will compare regional citrate anticoagulation (RCA) and standard heparin anticoagulation (HA) during postdilution hemodiafiltration (HDF) in chronic dialysis patients with end-stage kidney disease.Read full original descriptionShow less
Efficiency and Biocompatibility of Postdilution Hemodiafiltration Using Different Anticoagulation Methods: A Randomized Crossover Clinical Trial
This randomized crossover clinical trial will compare regional citrate anticoagulation (RCA) and standard heparin anticoagulation (HA) during postdilution hemodiafiltration (HDF) in chronic dialysis patients with end-stage kidney disease.
The primary aim of the study is to evaluate biocompatibility during HDF by measuring markers of complement activation (C3a), platelet activation (PF4), and coagulation activation (thrombin-antithrombin complex, TAT).
Secondary aims include comparison of solute removal efficiency, including beta-2 microglobulin, phosphate, and urea removal, as well as assessment of citrate, calcium, and magnesium kinetics during citrate anticoagulation.
Twenty adult chronic dialysis patients will undergo two study HDF procedures in randomized order: one procedure using heparin anticoagulation and one procedure using regional citrate anticoagulation with a one-week interval between procedures.
The study aims to improve understanding of the effects of anticoagulation methods on hemodiafiltration biocompatibility and dialysis efficiency and may contribute to optimization of citrate anticoagulation protocols in chronic hemodiafiltration patients.
Inclusion: Adults aged 18 years or older; End-stage kidney disease requiring maintenance postdilution hemodiafiltration; Stable chronic hemodialysis treatment three times weekly; Functional arteriovenous fistula.
Exclusion: Therapeutic anticoagulation therapy; Dual antiplatelet therapy; Active bleeding; Significant coagulopathy; Acute kidney injury.